US equities |
SPCX $166.71 ▲+4.88% NVDA $236.95 ▲+1.28% MU $1,063.97 ▼-1.02% TSLA $375.66 ▲+1.37% MSFT $526.01 ▲+1.64% INTC $116.94 ▼-2.00% SNDK $1,718.11 ▼-0.11% META $743.14 ▲+2.07%
FinancialContent

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

56.56 -0.60 (-1.05%)
Delayed Quote Updated: 10:44 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Insiders Selling TransMedics Group And 2 Other Stocks ↗
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Preview: Royalty Pharma's Earnings ↗
 
Via Benzinga
Ominous Death Cross Forms On Royalty Pharma's Chart ↗
 
Via Benzinga
Looking Into Royalty Pharma's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Royalty Pharma Reports Q4 and Full Year 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Five Best And Worst Performing Healthcare Stocks In December 2022 ↗
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
News headline image
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
From Royalty Pharma plc
Via GlobeNewswire
News headline image
6 Stocks Warren Buffett Completely Exited in 2022 ↗
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio. 
Via The Motley Fool
News headline image
Royalty Pharma Announces Expansion of Senior Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Royalty Pharma Reports Third Quarter 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
From Royalty Pharma plc
Via GlobeNewswire
News headline image
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position ↗
There may be more trouble on the horizon for these stocks than most investors are seeing right now. 
Via The Motley Fool
News headline image
Royalty Pharma Declares Fourth Quarter 2022 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added. 
Via Benzinga
News headline image
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces R&D Funding Collaboration With Merck
Novel collaboration structure supports pipeline innovation 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗
 
Via Benzinga
News headline image
Royalty Pharma's Return On Capital Employed Insights ↗
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters. 
Via Benzinga
News headline image
Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals ↗
Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >